ClinicalTrials.gg
CompletedNCT00760877Updated Nov 8, 2016Results posted

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

A Phase 3 interventional study of Nilotinib and Imatinib in CHRONIC MYELOGENOUS LEUKEMIA, sponsored by Novartis Pharmaceuticals. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
11th of 66
207 · median 55
Started
2009
with 7 others
Phase 3
15 of 66
none open now
Registered
12th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 11th largest by enrollment, is one of 8 that started in 2009, is one of 15 in phase 3, and was the 12th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The primary goal of this study was to determine the rate of confirmed best cumulative complete molecular response (CMR) within the first year of study therapy with imatinib or nilotinib. The study also explored the impact and significance of the achieved CMR on patient outcomes (progression free survival (PFS), event free survival (EFS) and overall survival (OS), characterized the kinetics of CMR achieved in both treatment arms and after the cross-over.

03

Conditions studied

  • CHRONIC MYELOGENOUS LEUKEMIA

Keywords

  • MYELOGENOUS
  • LEUKEMIA
  • Chronic Phase
  • CML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of chronic myeloid leukemia associated with BCR-ABL quantifiable by RQ-PCR Documented CCyR by bone marrow or BCR-ABL\<1% IS in the past 12 months Persistent disease demonstrated by two PCR positive tests 3 months apart both during the past 6 months.

Treatment with imatinib for at least 2 years with 400 mg or 600 mg and a stable dose No other current or planned anti-leukemia therapies

Exclusion criteria

Exclusion Criteria:

Patient has evidence of rising PCR (a confirmed >1 log increase in previous 6 months) Patient has received another agent within last 6 months or tyrosine kinase inhibitors (TKIs) other than imatinib Prior stem cell transplantation

Impaired cardiac function including any one of the following:

Inability to monitor the on (ECG) Long QT syndrome or a known family history of long QT syndrome. resting brachycardia (\<50 beats per minute) QTc > 450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc Myocardial infarction within 12 months prior to starting study Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension) History of or presence of clinically significant ventricular or atrial tachyarrhythmias Administration of cytokine therapy (e.g. G-CSF, GM-CSF or SCF) within 4 weeks prior to study entry

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.

    Drug: Nilotinib

  • Active comparator
    Imatinib

    Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.

    Drug: Imatinib

Interventions

  • Supplied in 200 mg capsules

  • Supplied in 100 mg and 400 mg capsules

    Also known as: Glivec/Gleevec

06

What researchers measure

Primary outcomes

  1. Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)

    The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity \>4.5 logs.

    Time frame: 12 months

Secondary outcomes

  1. Rate of Confirmed Best Cumulative CMR

    The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the 24, 36 and 48 months post treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity \>4.5 logs.

    Time frame: 24 months, 36 month, 48 months

  2. Number of Cross-over Participants With CMR

    The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity \>4.5 logs.

    Time frame: 24 months, 36 months, 48 months

  3. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of the earliest documented progression-defining event as follows: transformation to blast crisis or accelerated phase disease, or death from any cause.

    Time frame: 48 months

  4. Event-free Survival

    Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest.

    Time frame: 48 months

  5. Overall Survival

    Overall survival was defined as the time from the date of randomization to the date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.

    Time frame: 48 months

07

Results

Posted Aug 16, 2016

Participant flow

Participant flow — Overall Study
MilestoneNilotinibImatinib
Started104103
Cross-over to nilotinib046
Safety set101103
Completed5977
Not completed4526
Withdrew: Protocol violation10
Withdrew: Non-compliance with protocol treatment21
Withdrew: Pregnancy14
Withdrew: Death21
Withdrew: Withdrawal by subject73
Withdrew: Adverse event1912
Withdrew: Participant diagnosed with aml01
Withdrew: Participant not eligible to cross-over01
Withdrew: Physician decision12
Withdrew: Participants transferred to amn107a2408111
Withdrew: Treatment failure10

Outcome measures

PrimaryRate of Confirmed Best Cumulative Complete Molecular Response (CMR)

The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity \>4.5 logs.

Time frame:
12 months
Reported as:
Number · Participants
Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)
ParticipantsNilotinibImatinib
Responders136
Non-responders9197
Statistical analysis
  • Nilotinib vs Imatinib · Cochran-Mantel-Haenszel · p = 0.1083 · Odds ratio (or): 2.096 · 95% CI 0.766 to 5.738
SecondaryRate of Confirmed Best Cumulative CMR

The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the 24, 36 and 48 months post treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity \>4.5 logs.

Time frame:
24 months, 36 month, 48 months
Reported as:
Number · Participants
Rate of Confirmed Best Cumulative CMR
ParticipantsNilotinibImatinib
24 months, Responders2411
24 months, Non-responders8092
36 months, Responders2921
36 months, Non-responders7582
48 months, Responders3221
48 months, Non-responders7282
SecondaryNumber of Cross-over Participants With CMR

The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity \>4.5 logs.

Time frame:
24 months, 36 months, 48 months
Reported as:
Number · Participants
Number of Cross-over Participants With CMR
ParticipantsNilotinib
24 months3
36 months6
48 months9
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of the earliest documented progression-defining event as follows: transformation to blast crisis or accelerated phase disease, or death from any cause.

Time frame:
48 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsNilotinibImatinib
Progression Free Survival (PFS)NA (NA to NA)NA (NA to NA)
SecondaryEvent-free Survival

Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest.

Time frame:
48 months
Reported as:
Median · Months
Event-free Survival
MonthsNilotinibImatinib
Event-free SurvivalNA (NA to NA)NA (NA to NA)
SecondaryOverall Survival

Overall survival was defined as the time from the date of randomization to the date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.

Time frame:
48 months
Reported as:
Median · Months
Overall Survival
MonthsNilotinibImatinib
Overall SurvivalNA (NA to NA)NA (NA to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib—21/101 (20.8%)99/101 (98%)
Imatinib—16/103 (15.5%)79/103 (76.7%)
Imatinib Subset That Crossed Over to Nilotinib—8/46 (17.4%)39/46 (84.8%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventNilotinibImatinibImatinib Subset That Crossed Over to Nilotinib
ACUTE CORONARY SYNDROMECardiac disorders1/1010/1031/46
ATRIAL FLUTTERCardiac disorders0/1010/1031/46
ANAL FISSUREGastrointestinal disorders0/1010/1031/46
PYREXIAGeneral disorders0/1010/1031/46
CHOLECYSTITISHepatobiliary disorders0/1010/1031/46
PNEUMONIAInfections and infestations0/1011/1031/46
BACK INJURYInjury, poisoning and procedural complications0/1010/1031/46
DRUG ADMINISTRATION ERRORInjury, poisoning and procedural complications0/1010/1031/46
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders0/1010/1031/46
CEREBROVASCULAR ACCIDENTNervous system disorders1/1010/1031/46
Most frequent other events
Showing 10 of 57
Most frequent other events
EventNilotinibImatinibImatinib Subset That Crossed Over to Nilotinib
HEADACHENervous system disorders43/10113/1038/46
PRURITUSSkin and subcutaneous tissue disorders30/1010/1032/46
RASHSkin and subcutaneous tissue disorders30/1014/1039/46
NAUSEAGastrointestinal disorders22/10116/1034/46
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations20/10114/1037/46
DRY SKINSkin and subcutaneous tissue disorders20/1010/1033/46
ALANINE AMINOTRANSFERASE INCREASEDInvestigations19/1015/1038/46
LIPASE INCREASEDInvestigations19/10113/1037/46
DIARRHOEAGastrointestinal disorders14/10119/1034/46
MUSCLE SPASMSMusculoskeletal and connective tissue disorders15/10118/1031/46

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NilotinibImatinibTotal
Mean48.3 ± 13.2649.9 ± 13.0749.1 ± 13.16
Sex: Female, Male
Sex: Female, Male(Participants)NilotinibImatinibTotal
Female333871
Male7165136
08

Study locations

30 sites
  • Novartis Investigative Site
    Caba, Buenos Aires C1221ADH, Argentina
  • Novartis Investigative Site
    St. Leonards, New South Wales 2065, Australia
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
  • Novartis Investigative Site
    South Brisbane, Queensland 4101, Australia
  • Novartis Investigative Site
    Woolloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Prahran, Victoria 3181, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Belo Horizonte, MG 30130-100, Brazil
  • Novartis Investigative Site
    Curitiba, PR 80060-900, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 21941-913, Brazil
  • Novartis Investigative Site
    Campinas, SP 13083-970, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 05403-000, Brazil
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8H 4J9, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Québec, Quebec G1J 1Z4, Canada
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Creteil, 94010, France
  • Novartis Investigative Site
    Lyon cedex 04, 69317, France
  • Novartis Investigative Site
    Paris, 75010, France
  • Novartis Investigative Site
    Vandoeuvre les Nancy, 54511, France
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Barcelona, Cataluña 08036, Spain
  • Novartis Investigative Site
    Pamplona, Navarra 31008, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
  • Novartis Investigative Site
    Madrid, 28007, Spain
09

References and documents

Publications

  • Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudlo T, Leber B. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014 Jul 31;124(5):729-36. doi: 10.1182/blood-2013-12-544015. Epub 2014 Jun 19. PubMed 24948656 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2008
First posted
Sep 26, 2008
Start
Jun 2009
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Aug 16, 2016
Last update
Nov 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00760877
Responsible party
Sponsor
First posted
Sep 26, 2008
Start date
Jun 2009
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Aug 16, 2016
Last update
Nov 8, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion